A Phase 3 interventional study of Ferric carboxymaltose and Iron sucrose in Iron Deficiency Anemia, sponsored by Vifor (International) Inc.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-10.
Sponsored by Vifor (International) Inc. (part of CSL Limited) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency — 7 open to participants now, 7 under way, none of them phase 3. ferric carboxymaltose · Anemia, Iron-Deficiency.
Among the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency, this one is the 12th largest by enrollment, is one of 9 that started in 2017, is one of 16 in phase 3, and was the 30th registered.
601 studies on the registry are indexed under Anemia, Iron-Deficiency; 96 are open to participants now.
Browse Anemia, Iron-Deficiency studies →7 of the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency are open now, in 1 country. Recruiting first, the newest first:
Western Galilee Hospital-Nahariya · Sites in Israel
Ages 18–50 · Women only
Hawler Medical University
Ages 18–45 · Women only
Zhaojian Niu,MD
Ages 18–75
Children's Hospital of Orange County
Ages 1–18
Liverpool Hope University
Ages 60–85
By country, each count listing its studies:
ferric carboxymaltose: first FDA approval 2013 (INJECTAFER). What it is approved for, and how studies give it, is on its page →
Of the 55 Anemia, Iron-Deficiency studies recruiting now, 19 (35%) set no upper age limit and 32 (58%) stop at 75 or younger; 16 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
57 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 9 · Phase 3 17 · Phase 4 24
First in 2006; this study’s year is marked. 9 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 371 is above the median of 100 across 460 interventional studies indexed under Anemia, Iron-Deficiency.
Median enrollment 100 across the 57 interventional studies. Of the 45 that completed or were terminated, 15 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 57 have an industry lead sponsor. The 10 most frequent:
This study is registered under Vifor (International) Inc., one of the names counted as CSL Limited. Under that name alone:
Vifor (International) Inc. is the lead sponsor of 10 studies on the registry; none are open to participants now.
10 studies in Anemia, Iron-Deficiency by CSL Limited: none open now, none under way, none of them phase 3. Of 9 finished, 2 (22%) have results posted.
Among the 10 studies in Anemia, Iron-Deficiency by CSL Limited, this one is the 6th largest by enrollment, is the only one that started in 2017, is one of 6 in phase 3, and was the 8th registered.
CSL Limited’s Anemia, Iron-Deficiency studies by the year they started, since 2006.
2 of the studies testing ferric carboxymaltose in Anemia, Iron-Deficiency that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06061393Western Galilee Hospital-NahariyaComparison Between Outcomes of Pregnant Women Treated With Ferinject vs. Venofer for Iron Deficiency Anemia | 2027-09 |
| NCT07772453Zhaojian Niu,MDFerric Carboxymaltose Versus Iron Sucrose for Iron Deficiency Anemia After Radical Gastrectomy for Gastric Cancer | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 57 studies testing ferric carboxymaltose in Anemia, Iron-Deficiency, from their registry updates:
Among CSL Limited’s 10 in Anemia, Iron-Deficiency:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective is to demonstrate the efficacy of ferric carboxymaltose (FCM) given in a simple dosing regimen in correcting iron deficiency anaemia (IDA), by demonstrating non-inferiority to treatment with the currently approved intravenous (IV) iron therapy of iron sucrose (IS, Venofer™) in the Chinese population. The secondary objectives are to assess the safety of FCM compared to IS in the Chinese population and to evaluate the effect of FCM compared to IS on relevant laboratory parameters (haematology, chemistry, iron parameters) in the Chinese population.
This is an open-label, randomised controlled study to assess the impact of FCM in correcting iron deficiency anaemia compared with Venofer™ (IS).
All subjects, after providing written informed consent and meeting the eligibility assessments, will receive a first dose of IV iron as either FCM or IS. A total of approximately 368 subjects (184 per group) will be enrolled. All subjects will have iron deficiency anaemia as measured by haemoglobin (Hb), serum ferritin and transferrin saturation (TSAT) at screening.
Ferric carboxymaltose will be administered as either a diluted infusion or undiluted injection (at Investigator discretion) and IS will be administered as a slow intravenous injection at a rate of 1 ml undiluted solution per minute (with each single injection of 200 mg iron) or by drip infusion. Note, for subjects randomised to receive IS dosing visits are required three times a week to achieve total iron repletion dosing as calculated using the Ganzoni formula.
For subjects randomised to FCM, the total iron requirements will be calculated at screening based on the screening Hb and subject weight. Dosing will be at baseline and, if required, at day 8 and day 15. All subjects will attend study visits at screening, baseline and thereafter at Weeks 2, 4 and 6. All subjects will attend an end of study visit (at Week 8 - or earlier if discontinued prematurely).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects treated with FCM given by IV injection or drip infusion
Drug: Ferric carboxymaltose
Subjects treated with IS given by IV injection or drip infusion
Drug: Iron sucrose
Dosage Form: Injection, Sterile FCM solution as a 5% w/v iron solution in water for injection Strength: 10 mL vials containing 500 mg iron per vial Dosage: 500mg/week or 1000mg/week (based on subject BW and Hb value at screening) Route of administration: IV injection (undiluted solution) or drip infusion (500 mg iron diluted in 100 mL 0.9% w/v physiological saline or 1,000 mg iron diluted in 250 mL 0.9% w/v physiological saline) Dosing schedules: baseline (Day 1) and, if required, at Day 8 and Day 15.
Also known as: FCM
Dosage Form: Sterile solution for injection containing 2% w/v iron Strength: 5 mL ampoules containing 100 mg iron per ampoule Dosage: single doses of IS of 200mg iron based on the formula of Ganzoni: Cumulative iron deficit \[mg\] = BW \[kg\] x (target Hb- actual Hb) \[g/dL\] x 2.4 + 500 mg, up to 11 IS injections will be given Route of administration: IV injection or drip infusion Dosing schedules: three times a week, with an initial dose at baseline and will receive iron, as per approved label, until the subject has received the calculated iron dose.
Also known as: IS, Venofer™
Participants Achieving an Increase in Hb of at Least 2 g/dL at Any Time up to Week 8
Haemoglobin (Hb)
Time frame: From baseline at any time up to Week 8
Participants Achieving an Increase in Hb of at Least 2 g/dL From Baseline to Weeks 2, 4, 6 and 8
Haemoglobin (Hb)
Time frame: From Baseline to weeks 2, 4, 6 and 8
Change in Hb From Baseline to Weeks 2, 4, 6, and 8
Haemoglobin (Hb)
Time frame: From Baseline to weeks 2, 4, 6 and 8
Participants With Iron Deficiency Correction Over Time by Treatment
Iron deficiency correction: TSAT \>= 16% and serum ferritin \>=100ng/mL (for subjects with underlying inflammatory disease) or \>14ng/mL (for subjects with no apparent underlying inflammatory disease).
Time frame: From Baseline to Weeks 2, 4, 6 and 8
Change in TSAT From Baseline to Weeks 2, 4, 6 and 8
Transferrin saturation (TSAT)
Time frame: From Baseline to weeks 2, 4, 6 and 8
Change in Serum Ferritin From Baseline to Weeks 2, 4, 6 and 8
Time frame: From Baseline to Weeks 2, 4, 6 and 8
Change in Serum Iron From Baseline to Weeks 2, 4, 6 and 8
Time frame: From Baseline to weeks 2, 4, 6 and 8
Participants With Any Treatment Emergent Adverse Event (TEAE)
Please note that in this section we are presenting just the overview of the adverse events experienced by the trial participant, in particular, the number of participants with at least one TEAE until end of the trial. Please refer to the detailed tables included on the Adverse Event Module for specifics
Time frame: From Baseline to the End of the study (week 8)
Blood Pressure at Baseline and Weeks 2, 4, 6 and 8
Diastolic Blood pressure
Time frame: Baseline and weeks 2, 4, 6 and 8
Body Weight at Baseline and Week 8
Time frame: Baseline and week 8
Heart Rate at Baseline and Weeks 2, 4, 6 and 8
Time frame: Baseline and weeks 2, 4, 6 and 8
Body Temperature at Baseline and Weeks 2, 4, 6 and 8
Time frame: Baseline and weeks 2, 4, 6 and 8
| Milestone | Ferric Carboxymaltose (FCM) | Iron Sucrose (IS) |
|---|---|---|
| Started | 188 | 183 |
| Completed | 181 | 174 |
| Not completed | 7 | 9 |
| Withdrew: Adverse event | 5 | 3 |
| Withdrew: Protocol violation | 2 | 1 |
| Withdrew: Withdrawal by subject | 0 | 5 |
Haemoglobin (Hb)
| Participants | Ferric Carboxymaltose (FCM) | Iron Sucrose (IS) |
|---|---|---|
| Participants Achieving an Increase in Hb of at Least 2 g/dL at Any Time up to Week 8 | 176 | 175 |
Haemoglobin (Hb)
| Participants | Ferric Carboxymaltose (FCM) | Iron Sucrose (IS) |
|---|---|---|
| Week 2 | 150 | 129 |
| Week 4 | 164 | 167 |
| Week 6 | 169 | 168 |
| Week 8 | 173 | 171 |
Haemoglobin (Hb)
| g/dL | Ferric Carboxymaltose (FCM) | Iron Sucrose (IS) |
|---|---|---|
| Week 2 | 3.01 ± 1.135 | 2.53 ± 1.016 |
| Week 4 | 4.46 ± 1.502 | 4.08 ± 1.217 |
| Week 6 | 4.96 ± 1.435 | 4.61 ± 1.422 |
| Week 8 | 5.09 ± 1.504 | 4.87 ± 1.525 |
Iron deficiency correction: TSAT \>= 16% and serum ferritin \>=100ng/mL (for subjects with underlying inflammatory disease) or \>14ng/mL (for subjects with no apparent underlying inflammatory disease).
| Participants | Ferric Carboxymaltose (FCM) | Iron Sucrose (IS) |
|---|---|---|
| Week 2 | 173 | 135 |
| Week 4 | 165 | 168 |
| Week 6 | 161 | 163 |
| Week 8 | 162 | 154 |
Transferrin saturation (TSAT)
| Percentage of TSAT | Ferric Carboxymaltose (FCM) | Iron Sucrose (IS) |
|---|---|---|
| Week 2 | 30.16 ± 11.741 | 25.03 ± 19.474 |
| Week 4 | 28.00 ± 8.528 | 25.30 ± 8.453 |
| Week 6 | 25.50 ± 9.097 | 23.33 ± 7.868 |
| Week 8 | 25.32 ± 10.793 | 20.82 ± 7.618 |
| ng/ml | Ferric Carboxymaltose (FCM) | Iron Sucrose (IS) |
|---|---|---|
| Week 2 | 759.72 ± 331.118 | 385.51 ± 145.647 |
| Week 4 | 379.31 ± 195.415 | 280.58 ± 148.913 |
| Week 6 | 255.71 ± 152.582 | 184.93 ± 100.677 |
| Week 8 | 202.09 ± 148.382 | 145.56 ± 89.890 |
| umol/L | Ferric Carboxymaltose (FCM) | Iron Sucrose (IS) |
|---|---|---|
| Week 2 | 15.53 ± 7.075 | 16.23 ± 14.512 |
| Week 4 | 12.31 ± 4.209 | 12.39 ± 4.724 |
| Week 6 | 10.77 ± 4.318 | 11.27 ± 4.160 |
| Week 8 | 10.77 ± 4.871 | 10.09 ± 4.152 |
Please note that in this section we are presenting just the overview of the adverse events experienced by the trial participant, in particular, the number of participants with at least one TEAE until end of the trial. Please refer to the detailed tables included on the Adverse Event Module for specifics
| Participants | Ferric Carboxymaltose (FCM) | Iron Sucrose (IS) |
|---|---|---|
| Participants With Any Treatment Emergent Adverse Event (TEAE) | 124 | 101 |
Diastolic Blood pressure
| mmHg | Ferric Carboxymaltose (FCM) | Iron Sucrose (IS) |
|---|---|---|
| Baseline | 69.8 ± 7.91 | 71.9 ± 8.85 |
| Week 2 | 71.0 ± 8.33 | 72.6 ± 8.79 |
| Week 4 | 72.1 ± 7.60 | 73.8 ± 9.57 |
| Week 6 | 71.6 ± 8.18 | 74.3 ± 9.24 |
| Week 8 | 72.4 ± 8.09 | 74.1 ± 9.77 |
| kg | Ferric Carboxymaltose (FCM) | Iron Sucrose (IS) |
|---|---|---|
| Baseline | 59.76 ± 9.384 | 60.40 ± 9.354 |
| Week 8 | 59.73 ± 9.316 | 60.64 ± 9.372 |
| beats/min | Ferric Carboxymaltose (FCM) | Iron Sucrose (IS) |
|---|---|---|
| Baseline | 81.4 ± 8.85 | 82.2 ± 9.94 |
| Week 2 | 76.3 ± 9.80 | 76.5 ± 8.83 |
| Week 4 | 75.5 ± 10.71 | 76.6 ± 10.79 |
| Week 6 | 76.0 ± 8.98 | 77.2 ± 10.04 |
| Week 8 | 75.8 ± 10.33 | 77.5 ± 10.94 |
| ºC | Ferric Carboxymaltose (FCM) | Iron Sucrose (IS) |
|---|---|---|
| Baseline | 36.94 ± 0.292 | 36.45 ± 0.325 |
| Week 2 | 36.48 ± 0.269 | 36.44 ± 0.288 |
| Week 4 | 36.49 ± 0.269 | 36.40 ± 0.268 |
| Week 6 | 36.47 ± 0.259 | 36.41 ± 0.260 |
| Week 8 | 36.48 ± 0.269 | 36.46 ± 0.257 |
Collected over From Baseline until the End of the Study (8 weeks). Non-serious events are listed at a 2.0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ferric Carboxymaltose (FCM) | 0/187 (0%) | 10/187 (5.3%) | 124/187 (66.3%) |
| Iron Sucrose (IS) | 0/180 (0%) | 7/180 (3.9%) | 92/180 (51.1%) |
| Event | Ferric Carboxymaltose (FCM) | Iron Sucrose (IS) |
|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 1/187 | 2/180 |
| MenorrhagiaReproductive system and breast disorders | 0/187 | 2/180 |
| Abdominal adhesionsGastrointestinal disorders | 0/187 | 1/180 |
| AdenomyosisReproductive system and breast disorders | 0/187 | 1/180 |
| Pelvic adhesionsReproductive system and breast disorders | 0/187 | 1/180 |
| Anaphylactic shockImmune system disorders | 0/187 | 1/180 |
| Urinary tract infectionInfections and infestations | 0/187 | 1/180 |
| PyrexiaGeneral disorders | 0/187 | 1/180 |
| Adenocarcinoma of colonNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/187 | 0/180 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/187 | 0/180 |
| Event | Ferric Carboxymaltose (FCM) | Iron Sucrose (IS) |
|---|---|---|
| HypophosphataemiaMetabolism and nutrition disorders | 19/187 | 5/180 |
| Upper respiratory tract infectionInfections and infestations | 15/187 | 13/180 |
| Urine phosphorus decreasedInvestigations | 14/187 | 14/180 |
| Blood phosphorus decreasedInvestigations | 13/187 | 1/180 |
| Hepatic function abnormalHepatobiliary disorders | 13/187 | 9/180 |
| PyrexiaGeneral disorders | 12/187 | 3/180 |
| Alanine aminotransferase increasedInvestigations | 11/187 | 5/180 |
| White blood cells urine positiveInvestigations | 7/187 | 8/180 |
| Urinary tract infectionInfections and infestations | 6/187 | 7/180 |
| Aspartate aminotransferase increasedInvestigations | 7/187 | 4/180 |
Demography and baseline characteristics for the Safety Set (SS) are provided. The SS was defined as all randomised subjects who received at least 1 dose of study medication.
| Age, Continuous(years) | Ferric Carboxymaltose (FCM) | Iron Sucrose (IS) | Total |
|---|---|---|---|
| Mean | 39.9 ± 9.85 | 38.9 ± 8.70 | 39.4 ± 9.31 |
| Sex: Female, Male(Participants) | Ferric Carboxymaltose (FCM) | Iron Sucrose (IS) | Total |
|---|---|---|---|
| Female | 173 | 169 | 342 |
| Male | 14 | 11 | 25 |
| Race (NIH/OMB)(Participants) | Ferric Carboxymaltose (FCM) | Iron Sucrose (IS) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 187 | 180 | 367 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Ferric Carboxymaltose (FCM) | Iron Sucrose (IS) | Total |
|---|---|---|---|
| China | 187 | 180 | 367 |
| Haemoglobin(g/dl) | Ferric Carboxymaltose (FCM) | Iron Sucrose (IS) | Total |
|---|---|---|---|
| Mean | 7.74 ± 1.491 | 8.06 ± 1.453 | 7.90 ± 1.479 |
| Serum ferritin(ng/ml) | Ferric Carboxymaltose (FCM) | Iron Sucrose (IS) | Total |
|---|---|---|---|
| Mean | 4.47 ± 2.145 | 4.93 ± 6.095 | 4.70 ± 4.534 |
| Transferrin saturation (TSAT)(%) | Ferric Carboxymaltose (FCM) | Iron Sucrose (IS) | Total |
|---|---|---|---|
| Mean | 4.82 ± 1.898 | 4.92 ± 2.912 | 4.87 ± 2.446 |
| High-sensitivity C-reactive protein (hsCRP)(mg/l) | Ferric Carboxymaltose (FCM) | Iron Sucrose (IS) | Total |
|---|---|---|---|
| Mean | 1.026 ± 2.1432 | 1.567 ± 5.9817 | 1.291 ± 4.4617 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2017 to primary completion in Feb 2019, 19 months.
Results were first posted in May 2020, 1 year 2 months after primary completion.
Of 49 phase 3 interventional studies under Anemia, Iron-Deficiency, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 41. This study's 19 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ferric carboxymaltose